絞り込み

16645

広告

Real-time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations that Might be Targeted with Existing Drugs or Used as Biomarkers.

著者 Singhi AD , George B , Greenbowe JR , Chung J , Suh J , Maitra A , Klempner SJ , Hendifar A , Milind JM , Golan T , Brand RE , Zureikat AH , Roy S , Schrock AB , Miller VA , Ross JS , Ali SM , Bahary N
Gastroenterology.2019 Mar 02 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (15view , 0users)

Full Text Sources

Medical

Miscellaneous

It has been a challenge to select treatment for patients with pancreatic ductal adenocarcinomas (PDACs) based on genome alterations. We performed targeted genomic profile analyses of a large number of PDACs to assess the full spectrum of actionable genomic alterations METHODS: We performed targeted genomic profile analyses of 3594 PDAC samples from an international cohort, including capture-based targeted genomic profiling of as many as 315 cancer-associated genes and intron regions of 28 genes that are rearranged in cancer cells. Tumor mutation burden (TMB) and microsatellite instability (MSI) status were also assessed. TMB was calculated across a 1.14 Mb region; TMB-high (TMB-H) was defined as ≥20 mutations/Mb. MSI-high (MSI-H) status was assigned based on analysis of 114 intron homopolymer loci.
PMID: 30836094 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード